Benefits, issues, and recommendations for personalized medicine in oncology in Canada

C. Butts, S. Kamel-Reid, G. Batist, S. Chia, Charles Blanke, M. Moore, M. B. Sawyer, C. Desjardins, A. Dubois, J. Pun, K. Bonter, Fredrick D. Ashbury

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The burden of cancer for Canadian citizens and society is large. New technologies have the potential to increase the use of genetic information in clinical decision-making, furthering prevention, surveillance, and safer, more effective drug therapies for cancer patients. Personalized medicine can have different meanings to different people. The context for personalized medicine in the present paper is genetic testing, which offers the promise of refining treatment decisions for those diagnosed with chronic and life-threatening illnesses. Personalized medicine and genetic characterization of tumours can also give direction to the development of novel drugs. Genetic testing will increasingly become an essential part of clinical decision-making. In Canada, provinces are responsible for health care, and most have unique policies and programs in place to address cancer control. The result is inconsistency in access to and delivery of therapies and other interventions, beyond the differences expected because of demographic factors and clinical education. Inconsistencies arising from differences in resources, policy, and application of evidenceinformed personalized cancer medicine exacerbate patient access to appropriate testing and quality care. Geographic variations in cancer incidence and mortality rates in Canada-with the Atlantic provinces and Quebec having higher rates, and British Columbia having the lowest rates-are well documented. Our purpose here is to provide an understanding of current and future applications of personalized medicine in oncology, to highlight the benefits of personalized medicine for patients, and to describe issues and opportunities for improvement in the coordination of personalized medicine in Canada. Efficient and more rapid adoption of personalized medicine in oncology in Canada could help overcome those issues and improve cancer prevention and care. That task might benefit from the creation of a National Genetics Advisory Panel that would review research and provide recommendations on tests for funding or reimbursement, guidelines, service delivery models, laboratory quality assurance, education, and communication. More has to be known about the current state of personalized cancer medicine in Canada, and strategies have to be developed to inform and improve understanding and appropriate coordination and delivery. Our hope is that the perspectives emphasized in this paper will stimulate discussion and further research to create a more informed response.

Original languageEnglish (US)
JournalCurrent Oncology
Volume20
Issue number5
DOIs
StatePublished - 2013
Externally publishedYes

Fingerprint

Precision Medicine
Canada
Neoplasms
Genetic Testing
Hope
Education
British Columbia
Quebec
Quality of Health Care
Research
Communication
Demography
Guidelines
Technology
Delivery of Health Care
Drug Therapy
Mortality

Keywords

  • Genetic testing
  • Guidelines
  • Patient care
  • Personalized medicine
  • Policy
  • Practice
  • Quality

ASJC Scopus subject areas

  • Oncology

Cite this

Butts, C., Kamel-Reid, S., Batist, G., Chia, S., Blanke, C., Moore, M., ... Ashbury, F. D. (2013). Benefits, issues, and recommendations for personalized medicine in oncology in Canada. Current Oncology, 20(5). https://doi.org/10.3747/co.20.1253

Benefits, issues, and recommendations for personalized medicine in oncology in Canada. / Butts, C.; Kamel-Reid, S.; Batist, G.; Chia, S.; Blanke, Charles; Moore, M.; Sawyer, M. B.; Desjardins, C.; Dubois, A.; Pun, J.; Bonter, K.; Ashbury, Fredrick D.

In: Current Oncology, Vol. 20, No. 5, 2013.

Research output: Contribution to journalArticle

Butts, C, Kamel-Reid, S, Batist, G, Chia, S, Blanke, C, Moore, M, Sawyer, MB, Desjardins, C, Dubois, A, Pun, J, Bonter, K & Ashbury, FD 2013, 'Benefits, issues, and recommendations for personalized medicine in oncology in Canada', Current Oncology, vol. 20, no. 5. https://doi.org/10.3747/co.20.1253
Butts, C. ; Kamel-Reid, S. ; Batist, G. ; Chia, S. ; Blanke, Charles ; Moore, M. ; Sawyer, M. B. ; Desjardins, C. ; Dubois, A. ; Pun, J. ; Bonter, K. ; Ashbury, Fredrick D. / Benefits, issues, and recommendations for personalized medicine in oncology in Canada. In: Current Oncology. 2013 ; Vol. 20, No. 5.
@article{16bc23f675b04c199bcde4ca860eebf5,
title = "Benefits, issues, and recommendations for personalized medicine in oncology in Canada",
abstract = "The burden of cancer for Canadian citizens and society is large. New technologies have the potential to increase the use of genetic information in clinical decision-making, furthering prevention, surveillance, and safer, more effective drug therapies for cancer patients. Personalized medicine can have different meanings to different people. The context for personalized medicine in the present paper is genetic testing, which offers the promise of refining treatment decisions for those diagnosed with chronic and life-threatening illnesses. Personalized medicine and genetic characterization of tumours can also give direction to the development of novel drugs. Genetic testing will increasingly become an essential part of clinical decision-making. In Canada, provinces are responsible for health care, and most have unique policies and programs in place to address cancer control. The result is inconsistency in access to and delivery of therapies and other interventions, beyond the differences expected because of demographic factors and clinical education. Inconsistencies arising from differences in resources, policy, and application of evidenceinformed personalized cancer medicine exacerbate patient access to appropriate testing and quality care. Geographic variations in cancer incidence and mortality rates in Canada-with the Atlantic provinces and Quebec having higher rates, and British Columbia having the lowest rates-are well documented. Our purpose here is to provide an understanding of current and future applications of personalized medicine in oncology, to highlight the benefits of personalized medicine for patients, and to describe issues and opportunities for improvement in the coordination of personalized medicine in Canada. Efficient and more rapid adoption of personalized medicine in oncology in Canada could help overcome those issues and improve cancer prevention and care. That task might benefit from the creation of a National Genetics Advisory Panel that would review research and provide recommendations on tests for funding or reimbursement, guidelines, service delivery models, laboratory quality assurance, education, and communication. More has to be known about the current state of personalized cancer medicine in Canada, and strategies have to be developed to inform and improve understanding and appropriate coordination and delivery. Our hope is that the perspectives emphasized in this paper will stimulate discussion and further research to create a more informed response.",
keywords = "Genetic testing, Guidelines, Patient care, Personalized medicine, Policy, Practice, Quality",
author = "C. Butts and S. Kamel-Reid and G. Batist and S. Chia and Charles Blanke and M. Moore and Sawyer, {M. B.} and C. Desjardins and A. Dubois and J. Pun and K. Bonter and Ashbury, {Fredrick D.}",
year = "2013",
doi = "10.3747/co.20.1253",
language = "English (US)",
volume = "20",
journal = "Current Oncology",
issn = "1198-0052",
publisher = "Multimed Inc.",
number = "5",

}

TY - JOUR

T1 - Benefits, issues, and recommendations for personalized medicine in oncology in Canada

AU - Butts, C.

AU - Kamel-Reid, S.

AU - Batist, G.

AU - Chia, S.

AU - Blanke, Charles

AU - Moore, M.

AU - Sawyer, M. B.

AU - Desjardins, C.

AU - Dubois, A.

AU - Pun, J.

AU - Bonter, K.

AU - Ashbury, Fredrick D.

PY - 2013

Y1 - 2013

N2 - The burden of cancer for Canadian citizens and society is large. New technologies have the potential to increase the use of genetic information in clinical decision-making, furthering prevention, surveillance, and safer, more effective drug therapies for cancer patients. Personalized medicine can have different meanings to different people. The context for personalized medicine in the present paper is genetic testing, which offers the promise of refining treatment decisions for those diagnosed with chronic and life-threatening illnesses. Personalized medicine and genetic characterization of tumours can also give direction to the development of novel drugs. Genetic testing will increasingly become an essential part of clinical decision-making. In Canada, provinces are responsible for health care, and most have unique policies and programs in place to address cancer control. The result is inconsistency in access to and delivery of therapies and other interventions, beyond the differences expected because of demographic factors and clinical education. Inconsistencies arising from differences in resources, policy, and application of evidenceinformed personalized cancer medicine exacerbate patient access to appropriate testing and quality care. Geographic variations in cancer incidence and mortality rates in Canada-with the Atlantic provinces and Quebec having higher rates, and British Columbia having the lowest rates-are well documented. Our purpose here is to provide an understanding of current and future applications of personalized medicine in oncology, to highlight the benefits of personalized medicine for patients, and to describe issues and opportunities for improvement in the coordination of personalized medicine in Canada. Efficient and more rapid adoption of personalized medicine in oncology in Canada could help overcome those issues and improve cancer prevention and care. That task might benefit from the creation of a National Genetics Advisory Panel that would review research and provide recommendations on tests for funding or reimbursement, guidelines, service delivery models, laboratory quality assurance, education, and communication. More has to be known about the current state of personalized cancer medicine in Canada, and strategies have to be developed to inform and improve understanding and appropriate coordination and delivery. Our hope is that the perspectives emphasized in this paper will stimulate discussion and further research to create a more informed response.

AB - The burden of cancer for Canadian citizens and society is large. New technologies have the potential to increase the use of genetic information in clinical decision-making, furthering prevention, surveillance, and safer, more effective drug therapies for cancer patients. Personalized medicine can have different meanings to different people. The context for personalized medicine in the present paper is genetic testing, which offers the promise of refining treatment decisions for those diagnosed with chronic and life-threatening illnesses. Personalized medicine and genetic characterization of tumours can also give direction to the development of novel drugs. Genetic testing will increasingly become an essential part of clinical decision-making. In Canada, provinces are responsible for health care, and most have unique policies and programs in place to address cancer control. The result is inconsistency in access to and delivery of therapies and other interventions, beyond the differences expected because of demographic factors and clinical education. Inconsistencies arising from differences in resources, policy, and application of evidenceinformed personalized cancer medicine exacerbate patient access to appropriate testing and quality care. Geographic variations in cancer incidence and mortality rates in Canada-with the Atlantic provinces and Quebec having higher rates, and British Columbia having the lowest rates-are well documented. Our purpose here is to provide an understanding of current and future applications of personalized medicine in oncology, to highlight the benefits of personalized medicine for patients, and to describe issues and opportunities for improvement in the coordination of personalized medicine in Canada. Efficient and more rapid adoption of personalized medicine in oncology in Canada could help overcome those issues and improve cancer prevention and care. That task might benefit from the creation of a National Genetics Advisory Panel that would review research and provide recommendations on tests for funding or reimbursement, guidelines, service delivery models, laboratory quality assurance, education, and communication. More has to be known about the current state of personalized cancer medicine in Canada, and strategies have to be developed to inform and improve understanding and appropriate coordination and delivery. Our hope is that the perspectives emphasized in this paper will stimulate discussion and further research to create a more informed response.

KW - Genetic testing

KW - Guidelines

KW - Patient care

KW - Personalized medicine

KW - Policy

KW - Practice

KW - Quality

UR - http://www.scopus.com/inward/record.url?scp=84886881318&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886881318&partnerID=8YFLogxK

U2 - 10.3747/co.20.1253

DO - 10.3747/co.20.1253

M3 - Article

C2 - 24155644

AN - SCOPUS:84886881318

VL - 20

JO - Current Oncology

JF - Current Oncology

SN - 1198-0052

IS - 5

ER -